Related Experiment Videos
Progesterone: a novel adjunct to intravesical chemotherapy
1MDR Research Group, Department of Urology, Southampton University Hospital, Southampton, UK. mr@jlewin.fslife.co.uk
BJU International
|November 2, 2002
Summary
Progesterone reversed multidrug resistance (MDR) in urothelial cells. This steroid hormone may enhance intravesical chemotherapy effectiveness, offering a safer alternative for treating bladder cancer.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Intravesical chemotherapy failure in bladder cancer is often due to multidrug resistance (MDR).
- P-glycoprotein (PGP) is a key mediator of MDR, and its function can be modulated by steroid hormones.
- Progesterone, a steroid hormone, is investigated for its potential to overcome MDR.
Purpose of the Study:
- To investigate the effect of progesterone on multidrug-resistant urothelial cell lines.
- To assess progesterone's ability to reverse PGP-mediated MDR in vitro.
- To evaluate progesterone as an adjunct to intravesical chemotherapy.
Main Methods:
- Utilized two urothelial cell lines and their MDR sublines (RT112R, MGH-U1R).
- Assessed cytotoxic effects of progesterone, epirubicin, and their combination using tetrazolium-based assays and confocal microscopy.
- Evaluated MDR reversal in PGP-expressing cell lines.
Main Results:
- Progesterone demonstrated intrinsic cytotoxicity across all tested urothelial cell lines.
- Combined therapy with progesterone reversed epirubicin resistance in the MDR MGH-U1R cell line.
- MDR reversal was confirmed by both tetrazolium assays and confocal microscopy.
Conclusions:
- Progesterone effectively reverses multidrug resistance in urothelial cells in vitro.
- Progesterone's safety profile and effects on cell differentiation and apoptosis suggest its potential as an intravesical chemotherapy adjunct.
- Further research may establish progesterone as a valuable component in bladder cancer treatment regimens.